ARCHIMMUNE Trademark

Trademark Overview

On Monday, February 21, 2022, a trademark application was filed for ARCHIMMUNE with the United States Patent and Trademark Office. The USPTO has given the ARCHIMMUNE trademark a serial number of 97276905. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, February 24, 2025. This trademark is owned by Archimmune Therapeutics Inc.. The ARCHIMMUNE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development
archimmune

General Information

Serial Number97276905
Word MarkARCHIMMUNE
Filing DateMonday, February 21, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, February 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 10, 2023

Trademark Statements

Goods and ServicesConsulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 24, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameArchimmune Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421
Party NameArchimmune Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events

Event DateEvent Description
Wednesday, December 21, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, February 24, 2022NEW APPLICATION ENTERED
Thursday, February 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 5, 2022ASSIGNED TO EXAMINER
Monday, December 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 10, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 10, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, September 7, 2023SOU EXTENSION 1 FILED
Monday, October 9, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 10, 2023TEAS PETITION TO REVIVE RECEIVED
Tuesday, October 10, 2023PETITION TO REVIVE-GRANTED
Tuesday, October 10, 2023NOTICE OF REVIVAL - E-MAILED
Tuesday, October 10, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, October 10, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, October 11, 2023NOTICE OF REVIVAL - E-MAILED
Monday, October 23, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 26, 2023SOU EXTENSION 1 GRANTED
Friday, October 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 5, 2024SOU EXTENSION 2 FILED
Monday, February 5, 2024SOU EXTENSION 2 GRANTED
Wednesday, February 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 3 GRANTED
Tuesday, August 27, 2024SOU EXTENSION 3 FILED
Monday, February 24, 2025SOU TEAS EXTENSION RECEIVED
Monday, February 24, 2025SOU EXTENSION 4 FILED
Tuesday, February 25, 2025SOU EXTENSION 4 GRANTED
Monday, August 18, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, February 25, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED

Related Keywords

archimmune research development services pharmaceutical consulting field fields biotechnology biochemical vaccines